Basilea's Ceftobiprole Highlight of ICAAC Session
December 20, 2005 01:26 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Dec. 20, 2005 (PRIMEZONE) -- With new evidence of its potency against methicillin-resistant Staphylococcus aureus (MRSA) and broad spectrum of activity, ceftobiprole; in...
Basilea Maintains Global Commercialization Rights for BAL8557, its Novel Broad-Spectrum Antifungal Agent and Third Compound Entering Phase II
December 19, 2005 01:38 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Dec. 19, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today that it maintains global marketing and manufacturing rights to BAL8557 following Roche's...
Basilea's First-in-Class Antibiotic Ceftobiprole Aims at Broader Indication Including Diabetic Foot Infections
October 11, 2005 01:27 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Oct. 11, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) today announced the start of an additional pivotal Phase III trial with its development partner Johnson &...
Positive Results for Basilea's Novel Broad Spectrum Antifungal Agent
September 08, 2005 01:25 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Sept. 8, 2005 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. announced today positive results from its phase II clinical trial evaluating BAL8557, Basilea's broad-spectrum antifungal....
Basilea Pharmaceutica Ltd. Reports its Interim Results
August 24, 2005 01:29 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Aug. 24, 2005 (PRIMEZONE) -- Basilea realizes CHF 95.9 million from Johnson & Johnson under ceftobiprole license agreement in the first half of 2005; cash and short-term...
Ordinary General Meeting of Shareholders of Basilea Pharmaceutica AG
April 13, 2005 01:25 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, April 13, 2005 (PRIMEZONE) -- In his presentation to shareholders yesterday, Anthony Man, MD, Basilea's CEO, commented on the 2004 business year:
"The focus of Basilea over the...
Basilea's First-in-Class Antibiotic BAL5788 (Ceftobiprole) Moves into Hospital-Acquired Pneumonia Phase III Clinical Trials
April 08, 2005 01:22 ET
|
Basilea Pharmaceutica Ltd
Basel, Switzerland, April 8, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today the start of its international phase III program for BAL5788, a novel broad spectrum, anti-methicillin...
Basilea Announces 2004 Financial Results Reflecting Successful Investment in its Three Development Compounds, Bringing all Three Compounds One Phase Closer to the Market
March 10, 2005 02:02 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 10, 2005 (PRIMEZONE) -- Basilea:
Combined cash and short-term investments increased to CHF 203.2 million as of December 31, 2004 compared to CHF 75.5 million at year-end...
Basilea Investigates Novel Antibiotic Class with Potential to Treat Acne and Rosacea
March 08, 2005 01:30 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, March 8, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced the advancement of the novel topical antibiotic BAL19403 into preclinical testing. BAL19403 is the most advanced of...
Basilea Enters a Global Collaboration with Johnson & Johnson's Affiliate Cilag AG International for Basilea's Phase III, First-in-Class Antibiotic Ceftobiprole (BAL5788)
February 03, 2005 01:52 ET
|
Basilea Pharmaceutica Ltd
BASEL, Switzerland, Feb. 3, 2005 (PRIMEZONE) -- Basilea Pharmaceutica AG announced today that it has entered into an exclusive worldwide agreement with Cilag AG International, a Johnson & Johnson...